1. Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort.
- Author
-
Hagens, Marinus J., Stelwagen, Piter J., Veerman, Hans, Rynja, Sybren P., Smeenge, Martijn, van der Noort, Vincent, Roeleveld, Ton A., van Kesteren, Jolien, Remmers, Sebastiaan, Roobol, Monique J., van Leeuwen, Pim J., and van der Poel, Henk G.
- Subjects
- *
PROSTATE biopsy , *PROSTATE cancer - Abstract
The positive effect of the Rotterdam Prostate Cancer Risk Calculator (RPCRC)-3/4 and RPCRC-MRI has already been confirmed. Nevertheless, its performance and applicability in clinical practice are still questioned. This study performs an external validation of the RPCRC-3/4 and -MRI within a Dutch clinical high-risk cohort. Men (n = 1,575) subjected to prostate biopsies between 2018 and 2021 due to a clinical suspicion of prostate cancer (PCa) were retrospectively included. PCa and clinically significant PCa (csPCa) were diagnosed in 996/1,575 (63.2%) and 656/1,575 (41.7%) men, respectively. The analysis showed that the RPCRC-3/4 underestimates the risk of csPCa within this Dutch high-risk clinical cohort: even though the RPCRC-3/4 could have prevented 37.3% of all MRIs, 18.3% of csPCa diagnoses would have been consequently missed. Recalibration of this risk calculator and adjustment of its risk thresholds was therefore indicated. The RPCRC-MRI, on the other hand, performed adequately and recalibration was not necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF